Buying from a UK Wholesaler vs a UK Manufacturer Direct: What Actually Changes for an Overseas Hospital

If you run hospital pharmacy procurement, buy for a ministry of health or NGO programme, or import medicines for onward distribution, you have probably asked the obvious question: why not skip the intermediary and buy straight from the UK manufacturer? For a single high-volume product in one market, under a standing contract, that can be the right answer. For almost everything else, a hospital formulary basket, a mixed tender list, or a shortage line needed in weeks rather than months, the trade-offs below usually favour a UK wholesale exporter, even though it adds a margin. The comparison and the sources further down show why.

This guide covers what genuinely changes between the two routes, for buyers who already know how UK wholesale sourcing works and now need to make the route decision itself.

For transparency: Euro Biom Ltd is a UK MHRA-licensed pharmaceutical wholesale exporter, WDA(H) 59239, supplying only UK-licensed, MHRA-authorised finished medicines. We are not a manufacturer and we do not hold foreign registrations. We are also one of the two options discussed here, so we have been specific about where the other option wins.

The Short Answer

• Go direct when you need one or a few brands from one manufacturer, in volumes that meet or beat its own minimums, on a recurring schedule, into a market the manufacturer or its appointed local partner already supplies.
• Use a UK wholesale exporter when you need many molecules from many manufacturers, volumes below manufacturer minimums, urgent or intermittent supply, or when you have no existing account history with the manufacturer.
• Neither route works for a restricted or unlicensed line. See Export Restrictions below.

Side-by-Side Comparison

Exact terms vary by manufacturer, product and market, so treat this as a checklist rather than a fixed rule.

Will the Manufacturer Actually Sell to You?

The first practical question is not price, it is whether the manufacturer will open an account for you at all. Many UK manufacturers route their products through a deliberately narrow set of channels, and this is not new: the pattern goes back close to two decades. Pfizer moved to supplying UK pharmacies through a single distributor on a fee-for-service basis, and AstraZeneca to just two distributors (PharmExec). Bayer Schering Pharma cut its UK wholesaler panel to three distribution partners in 2009 (PharmaTimes).

Outside the UK, most manufacturers already have an appointed distributor or marketing partner in each market they serve. An approach from an overseas hospital is commonly redirected to that partner rather than fulfilled from the UK. That is a legitimate commercial choice, but "buying direct" then means buying from a distributor the manufacturer chose. If you are a distributor seeking territory rights from a manufacturer, that is a different relationship again, described from the other side on our manufacturer distribution arrangements page.

Allocation, Quotas and Your Place in the Queue

Allocation is the factor buyers most often underestimate. When supply is tight, stock is rationed across channels. UK community pharmacy saw this in 2020, when PSNC reported having received more than 320 reports relating to over 60 drugs where wholesaler and manufacturer quotas had hindered pharmacies' ability to source medicines (Pharmacy Magazine, October 2020).

Members of the Healthcare Distribution Association are responsible for distributing over 92% of NHS medicines (HDA UK), and a manufacturer managing a constrained product will protect that domestic channel first. A new overseas account with no order history is typically served only after established domestic channels are satisfied. A wholesale exporter's position depends on its own trading history with each manufacturer and supplier, so the honest answer to "can you get this line?" is given line by line at quotation, never as a blanket promise. For lines that are genuinely scarce, our hard-to-source medicines page explains how we approach them, and why some cannot be supplied at all.

UK Export Restrictions Apply to Both Routes

A persistent myth is that buying from the manufacturer gets around UK supply controls. It does not. The DHSC and MHRA maintain a published, regularly updated list of medicines that cannot be parallel exported from the UK or hoarded, because they are needed for UK patients and are in, or at risk of, shortage. Exporting a listed medicine without an exemption breaches regulation 43(2) of the Human Medicines Regulations 2012 and can lead to MHRA regulatory action, up to immediate suspension of the wholesale dealer licence (GOV.UK).

The practical conclusion is simple: a restricted product is unavailable for export whichever route you choose, and a UK supplier of either kind offering to export a listed line should be treated as a warning sign. Our article on UK medicine export restrictions in 2026 explains how the list works; the point here is only that it favours neither route.

CPP and Batch Documentation

Most destination regulators expect a Certificate of Pharmaceutical Product for a UK-licensed medicine. For a licensed product, the CPP application must include a letter on headed paper from the marketing authorisation holder giving permission to export on its behalf, either as a blanket permission or product by product (GOV.UK).

Buying direct from a single manufacturer, the authority question is straightforward for that brand. A basket covering many brands, however, means a separate conversation, permission letter and document set with every manufacturer on the list. Through a wholesale exporter, you deal with one counterparty that coordinates the CPP, GMP evidence and export documents across brands. The exporter still relies on each marketing authorisation holder's permission, but one party chases it instead of your team.

Batch documentation follows the same pattern. With Euro Biom, batch documentation is available for each line and confirmed at quotation, so you know what will accompany the consignment before you commit. For the full document set destination regulators expect, see our UK pharmaceutical import documentation guide and the regulator comparison tool. The time that legalisation and attestation add is covered in our article on document legalisation and attestation, and it applies equally to both routes.

Mixed-Brand Orders, Minimums and Lead Time

For a ministry of health tender list or a quarterly hospital restock, the question is rarely one product. It is dozens, often from many different UK manufacturers. Going direct to each manufacturer is generally impractical for a basket like this: each manufacturer sets its own minimums and supplies only its own portfolio, so a list of dozens of lines means dozens of separate accounts, orders and shipments.

Minimums scale with the manufacturer's commercial model: a UK manufacturer selling direct typically sets order minimums calibrated to a distributor or a national tender, not to a single hospital's formulary basket. That structure, not any specific quantity, is why direct export deals suit volume buyers rather than a hospital needing modest quantities of many lines within weeks.

Consolidation also simplifies the physical and quality side. One order produces one shipment, one set of GDP temperature records for any 2-8°C lines, one customs entry and one invoice, rather than one of each per manufacturer. For urgent orders driven by stock-outs, see our drug shortage supply page. Government and NGO buyers procuring at scale can see our tender and government supply page.

Traceability, Recalls and Who Does the Compliance Work

Under Good Distribution Practice, a UK wholesale distributor must qualify its suppliers and customers, keep full transaction records and trace every batch in both directions, with a nominated Responsible Person accountable for the quality system. The MHRA inspects wholesale distribution sites for GDP compliance and points distributors to the Green Guide, its Rules and Guidance for Pharmaceutical Distributors (GOV.UK). A WDA(H) is the legal authorisation for wholesale activity in human medicines, and its scope is defined licence by licence (GOV.UK). Euro Biom's WDA(H) 59239 covers procurement, supply and export of UK-licensed medicines, with stock held at a GDP-compliant contract storage site rather than a facility of our own. See our WDA licence and compliance pages for detail.

When you buy direct, much of that assurance work moves onto your side of the table. WHO procurement guidance recommends that any direct arrangement with a manufacturer be governed by a formal contract defining each party's responsibilities, and that the procurement agency verify the manufacturer will supply the product exactly as documented, with the same formulation and manufacturing site, as in the product dossier (WHO). That is work your team does, separately, for every manufacturer.

The risk on the other side is a longer, less visible chain. The stage where medicines are received, stored and handled between manufacturer and buyer is one of the most likely points for counterfeit product to enter the supply chain (IDLogiq), and every unverified local intermediary in a direct deal adds another such point. On a recall the test is simple: who can tell you quickly which of your consignments carried the affected batch? If you are vetting a UK supply line before choosing a route, our supplier qualification page covers what we provide, and our guide on how to verify a UK pharmaceutical supplier covers the licence checks.

Your Destination Market May Decide for You

In many GCC and African markets, the law places a locally licensed entity between any foreign manufacturer and the end buyer. Under the UAE's Federal Decree-Law No. 38 of 2024, in force since 2 January 2025, for example, a marketing authorisation holder must appoint at least two importers and one or more distributors, with the Emirates Drug Establishment authorising those activities (Baker McKenzie, January 2025). A UK manufacturer typically cannot simply ship to a UAE hospital without that local chain in place.

So "direct from the manufacturer" often means direct from the manufacturer's appointed local importer. That can work well, but you have exchanged a UK counterparty you selected and can audit for a local one the manufacturer selected. Where a UK-licensed medicine is not registered in your market at all, the route becomes your own named-patient or special-import application. Our named-patient supply page covers the UK-side mechanics of that import route, and our article on named-patient import versus local registration covers the separate market-entry decision.

When Going Direct Is the Better Choice

Stated plainly: there are situations where a wholesale exporter adds a margin with no matching service benefit, and you should go direct.

• One brand, one manufacturer, recurring volume. If you need a single product in volumes that meet or exceed the manufacturer's own minimum, on a standing schedule, a direct supply contract will usually give the best unit price.
• The manufacturer already serves your market. Where the product is registered locally and the marketing authorisation holder has an appointed importer you can buy through on acceptable terms, adding a UK wholesaler rarely helps.
• A multi-year tender award for one molecule. A long-term national award for a single registered product suits a direct contract with the manufacturer or its local licence holder.
• You need the manufacturer's own commitments. Contractual supply guarantees, dedicated allocation or market-specific packs can only come from the manufacturer itself.

If your situation fits one of these, approach the manufacturer or its local partner first. A wholesale exporter earns its place when the basket is broad, volumes are modest, time is short or you have no existing account.

What a Wholesale Exporter Cannot Do

• Export restricted lines. See Export Restrictions above; the rule applies to both routes.
• Supply unlicensed products. Euro Biom supplies only UK-licensed, MHRA-authorised finished medicines. We do not supply unlicensed medicines or specials, and our scope does not cover vaccines, biologics, biosimilars, insulin, blood or plasma products or controlled drugs.
• Override manufacturer allocation. No wholesaler can promise volume it has not been allocated. See Allocation above.
• Hold your registration or import permit. Destination-market registrations and import permissions sit with your local importer, hospital or marketing authorisation holder, not with a UK exporter.
• Beat a direct contract price on a single high-volume line. Where you qualify for direct terms, a wholesaler's price will usually be higher.

Questions to Ask Either Route

1. Will you sell to my organisation in my country, or will I be referred to a local partner?
2. What is the minimum order per line, and does it apply per shipment or per contract?
3. How is this line allocated when supply is short, and where does a new overseas account sit?
4. Is any line on my list subject to UK export restrictions?
5. Who obtains the CPP and the marketing authorisation holder's permission, and how long does that take?
6. What batch documentation comes with each line, and is it confirmed before I commit?
7. Can the order be consolidated into one shipment, with one temperature record and one document pack?
8. How will a recall be communicated to me, and how quickly can you identify affected consignments?
9. What payment terms apply to a new account, and does one account cover every brand?
10. Can I verify your licence on a public register? Euro Biom's authorisation can be checked on the MHRA register for WDA(H) 59239.

Where Euro Biom Fits

Euro Biom works with hospital pharmacies, ministries of health, NGOs and licensed importers across the GCC, Africa, the Levant, Turkey and Asia who need UK-licensed medicines from multiple manufacturers, with the documents their regulators expect, from one accountable UK counterparty. Distributors buying regularly can open a pharmaceutical trade account. For a specific basket, send us the list and we will quote it line by line.